Watch Adapthealth Corp for free: we tell you when fair value or trend changes.

Adapthealth Corp (AHCO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Adapthealth Corp stock $21.99, price $7.33, upside +200.0%, quality 40 out of 100. Rating: strongly undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

10 models, one by oneBear $12.60 to bull $45.90 Growth analysisrevenue history, year by year Quality 40/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

Thin data Nov 6, 2026

Adapthealth Corp

AHCO · US

Cheap, value-trap risk

The stock costs 67% less than our calculation considers fair.

Fair value $21.99 · Strongly undervalued (67%)

Generates free cash flow

Even on cautious assumptions the value is 72% above the price ($12.60).

Quality 40/100

Mixed Growth (revenue 5y +25.2 %/yr in USD)

Moderate debt

Insiders bought $393,130 (6M) · sold $231,138

Loss-making · -11.8% net margin (TTM) · excl. goodwill write-downs -3.9%

Trails peers (4/11)

Narrow moat 20/100

Thin data

Watch Adapthealth Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $5.22 – $27.25 · fair‑value band $12.60 – $45.90 · the $7.33 price screens below the $21.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Adapthealth in your weekly email

Every Wednesday you see whether Adapthealth is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments.

Show moreShow less

The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services; and medical devices, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; and other HME devices and supplies.

It also provides PAP machines, wheelchairs, hospital beds, oxygen concentrators, ventilators, insulin pumps, diabetes management and wound care supplies, orthopedic bracing, breast pumps and supplies, walkers, commodes, enteral supplies, and incontinence supplies.

The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. was founded in 2012 and is headquartered in Conshohocken, Pennsylvania.

Stock analysis

Adapthealth Corp (AHCO) currently trades at $7.33, while our model-based Fair Value estimate is $21.99, implying the stock looks roughly 67% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $25.82 per share, and 9 of the 10 models we run sit above the $7.33 price.

Bear case: the Multiples group reads lowest at $10.03, and 1 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: $12.60 (bear) to $45.90 (bull), the price of $7.33 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Adapthealth Corp reported revenue of $3.2B in FY2025 versus $2.5B in FY2021, a compound +7.2%/yr. Reported net income was −$70.8M in FY2025.

Key figures

Market cap $998M Small · P/S ratio 0.29 · EPS (TTM) $−3.27 · Net margin −11.8% · Return on equity −28.4% · Return on assets (EBIT) 1.0% (5-year average) · Operating margin 2.3% · Revenue (TTM) $3.4B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 200%, AHCO screens cheaper than that median.

Fair Value models

Bear $12.60 Fair Value $21.99 Bull $45.90

Price $7.33 · Upside +200.0%

Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF $14.79 $25.82 $58.15 74

Growth DCF $13.11 $27.72 $53.89 74

5Y EBITDA Exit $25.56 $56.96 $117.45 70

All 10 models by family

DCF Models

FCF DCF $14.79 $25.82 $58.15 74

5Y Revenue Exit $5.93 $16.66 $38.41 65

5Y EBITDA Exit $25.56 $56.96 $117.45 70

10Y Revenue Exit $8.50 $25.66 $36.89 65

10Y EBITDA Exit $21.27 $61.15 $135.23 62

Multiples

EV/EBIT $4.24 $10.03 $15.83 62

EV/EBITDA $30.54 $45.11 $59.67 66

EV/Revenue n/a $4.58 $9.90 50

Growth DCF

Growth DCF $13.11 $27.72 $53.89 74

Rev-Margin DCF $5.93 $20.77 $45.37 66

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19

How much profit the company makes from its sales and capital

Quality Growth 24

Are margins and returns getting better?

Cashflow 36

Do the profits arrive as real cash?

Financial strength 21

Debt, balance sheet and risk of trouble

Investment 82

Does it invest with discipline instead of growing at any price?

Low Volatility 19

How calm the share price moves, does not count

Price momentum 33

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 14

Distance to the 52-week high, does not count

New shares 76

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $393,130, most recently on Aug 7, 2026. Over the same period, one person sold shares worth $231,138. Buying cluster

BuyDale B WolfDirector3× since Feb 27, 2026: 48,000 shares, avg. $6.56$314,880Aug 7, 2026
BuyKenneth A SametDirector23,500 shares at $6.38$149,930Aug 6, 2026
SaleIII Russell E. SchusterChief Commercial Officer2× since Jun 1, 2026: 22,550 shares, avg. $10.25$231,138Jul 1, 202610b5-1 plan
BuyOEP VII Project A Co-Investment Partners, L.P.10% owner447,827 shares at $9.91$4.4MMar 20, 2026
BuyRichard M Cashin Jr10% owner2× since Mar 10, 2026: 2,494,518 shares, avg. $9.76$24.4MMar 20, 2026
BuyOEP VII General Partner, L.P.10% owner2,046,691 shares at $9.73$19.9MMar 12, 2026
BuyRichard W. Rew IICLO and General Counsel5,000 shares at $8.91$44,550Feb 26, 2026
SaleDavid Solomon Williams IIIDirector5,000 shares at $9.43$47,150Dec 4, 2025

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 56/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−0.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+25.2%

Start year 2020 (pandemic)

Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+38.4%

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

5.5% (2019) → 5.7% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

A lot of optimism in the price

The price assumes less growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+5.3%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+0.4%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.9% a year for the price and −1.9% for the forecasts.

Forecast 2026 (sales)−10.4%

Forecast 2027 (sales)+3.6%

Projected 2028 (sales)+3.4%

Projected 2029 (sales)+3.2%

Projected 2030 (sales)+3.0%

Watch AHCO, get fair value alerts →

Compare Adapthealth Corp with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 4/10 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 40 · Bottom 25%

Fair Value upside +200.0% · Top 25%

Profitability

Return on assets −1.6% · Below median

Net margin (12 months) −11.8% · Bottom 25%

Operating margin (12 months) 2.3% · Below median

Growth and dividend

Revenue growth (quarter YoY) −9.1% · Bottom 25%

Balance sheet

Debt / equity 1.13× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.66× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (12 months) 0.29× · Cheapest 25%

Price / free cash flow (fiscal year) 4.6× · Cheapest 25%

EV/EBITDA 4.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 6

FUTURE (revenue growth)0 · sector 35

PAST (return on equity)0 · sector 17

HEALTH (low debt)44 · sector 98

DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Stryker Corporation SYK	$325.87	$358.46	+10%	vs AHCO
Boston Scientific Corporation BSX	$42.75	$47.03	+10%	vs AHCO
DexCom, Inc DXCM	$79.41	$87.35	+10%	vs AHCO
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥184.15	¥197.22	+7%	vs AHCO
GE HealthCare Technologies Inc GEHC	$82.38	$69.92	−15%	vs AHCO
Edwards Lifesciences Corporation EW	$102.14	$81.94	−20%	vs AHCO
Siemens Healthineers AG SHL	€44.66	€34.95	−22%	vs AHCO
Abbott Laboratories, ABT	$109.93	$75.28	−32%	vs AHCO
Medtronic plc MDT	$101.80	$65.61	−36%	vs AHCO
Koninklijke Philips N.V PHIA	€27.33	€15.23	−44%	vs AHCO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Adapthealth Corp: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/AHCO?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/AHCO.US.svg" width="360" height="84" alt="Adapthealth Corp: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Adapthealth Corp Fair Value". https://www.fairvalue-calculator.com/stock/AHCO

Frequently asked questions

Is Adapthealth Corp (AHCO) overvalued or undervalued?

As of Nov 6, 2026, our model estimates a fair value of $21.99 versus a price of $7.33, about +200% upside (undervalued).

What is the fair value of AHCO?

Our model-based fair value for Adapthealth Corp is $21.99 (as of Nov 6, 2026), built from audited fundamentals. The current price: $7.33.

What is the quality score of AHCO?

Adapthealth Corp has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Adapthealth Corp (AHCO)?

Our model-based price target is the fair value of $21.99 (as of Nov 6, 2026) from 10 valuation models. Cautious scenario $12.60, optimistic scenario $45.90. It is a calculation from audited fundamentals, not an analyst target.

What is the Adapthealth Corp stock forecast for 2026?

Our models put fair value at $21.99, about +200% upside versus a price of $7.33 (undervalued). Cautious scenario $12.60, optimistic scenario $45.90. The calculation is refreshed regularly with new filings.

What is the revenue of Adapthealth Corp (AHCO)?

Adapthealth Corp reported trailing-twelve-month revenue of about $3.4B (latest available figure, as of Nov 6, 2026).

What growth is priced into Adapthealth Corp (AHCO)?

For today's price to be fair in a discounted-cash-flow model, Adapthealth Corp would have to grow free cash flow by +5.3 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.2 % per year. As of Nov 6, 2026.

What discount rate (WACC) does the fair value of AHCO use?

Our models discount Adapthealth Corp at 12.1 %: a base by market capitalisation (small), damped by beta 1.32, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Adapthealth Corp that is +5.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.

How much growth has Adapthealth Corp (AHCO) delivered so far?

Over the past 5 years revenue at Adapthealth Corp grew +25.2 % a year. The price currently implies free-cash-flow growth of +5.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Adapthealth Corp (AHCO) growing?

The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Adapthealth Corp (+5.3 % per year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Adapthealth Corp (AHCO)?

The free-cash-flow yield on the price is 21.99 %: that much free cash flow Adapthealth Corp produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Adapthealth Corp (AHCO)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Adapthealth Corp it is $21.99 per share (as of Nov 6, 2026), against a price of $7.33. It is the blended result of 10 valuation models in 3 families (DCF Models, Multiples, Growth DCF).

Is Adapthealth Corp stock overvalued or undervalued in 2026?

As of Nov 6, 2026, AHCO trades below its calculated fair value: price $7.33, fair value $21.99, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of AHCO?

No. The price is what the market pays today ($7.33); the fair value is what the company's own numbers justify ($21.99). For Adapthealth Corp the two are $14.66 per share apart. That gap is exactly why we show both numbers side by side.

How much is Adapthealth Corp worth?

The market values Adapthealth Corp at about $998M (market capitalisation, as of Nov 6, 2026). Per share that is $7.33; our models calculate a fair value of $21.99 per share.

What do the bullish and bearish scenarios say about AHCO?

Our models span a range for Adapthealth Corp: cautious scenario $12.60, base $21.99, optimistic $45.90 per share (as of Nov 6, 2026, price $7.33). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Adapthealth Corp (AHCO)?

Balance-sheet figures for Adapthealth Corp (as of Nov 6, 2026): return on equity −28.4%, debt of 1.13 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.

How far is AHCO from its 52-week high?

Adapthealth Corp trades at $7.33, about 45% below its 52-week high of $13.38 and 40% above the low of $5.22 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $21.99 is for.

Which stocks are comparable to Adapthealth Corp?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Adapthealth Corp stock attractive at the current price?

The data as of Nov 6, 2026: price $7.33, calculated fair value $21.99 (+200%), Quality Score 40/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of AHCO calculated?

We run Adapthealth Corp through 10 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of $21.99 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.0% above its aggregate fair value. Adapthealth Corp currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Adapthealth Corp (AHCO)?

The closing price on Nov 6, 2026 was $7.33. Our model-based fair value is $21.99, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Adapthealth Corp right now?

The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($12.60). The market is more pessimistic than our downside scenario. The model range is unusually wide ($12.60 to $45.90). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Adapthealth Corp

How large is the market capitalisation of Adapthealth Corp (AHCO)?

The market capitalisation of Adapthealth Corp is $998M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Adapthealth Corp (AHCO)?

The price-to-sales ratio of Adapthealth Corp is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Adapthealth Corp (AHCO)?

Earnings per share at Adapthealth Corp are $−3.27. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Adapthealth Corp (AHCO)?

The net margin of Adapthealth Corp is −11.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Adapthealth Corp (AHCO)?

The return on equity (ROE) of Adapthealth Corp is −28.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Adapthealth Corp (AHCO)?

On an EBIT basis the return on assets of Adapthealth Corp is 1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Adapthealth Corp (AHCO)?

The operating margin of Adapthealth Corp is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Adapthealth Corp (AHCO)?

Revenue at Adapthealth Corp is growing −9.1% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Adapthealth Corp (AHCO)?

Earnings per share at Adapthealth Corp are growing +6.7% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Adapthealth Corp (AHCO) carry?

The net debt of Adapthealth Corp is $1.8B (fiscal year 2025, ≈ 8.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Adapthealth Corp in the live analysis

One click puts Adapthealth Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.